Intravenous Versus Intra-peritoneal Dexamethasone on the Incidence of Postoperative Nausea and Vomiting

Effect of Intravenous Versus Intra-peritoneal Dexamethasone on the Incidence of Postoperative Nausea and Vomiting Following Laparoscopic Gynecological Surgeries

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02947672

Enrollment

100

Registered

2016-10-28

Start date

2016-11-30

Completion date

2017-11-30

Last updated

2018-02-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative Nausea and Vomiting

Brief summary

Effect of intravenous versus intra-peritoneal dexamethasone on the incidence of postoperative nausea and vomiting following Laparoscopic gynecological surgeries.

Interventions

DRUGIntravenous Dexamethasone

DRUGIntraperitoneal Dexamesathone

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 40 Years

Healthy volunteers

Inclusion criteria

1. Adult Female patients 2. American society of anesthesiologist class I & II 3. Undergoing Laparoscopic gynecological surgeries

Exclusion criteria

1. Patient refusal to participate in the study 2. Patients with coagulopathy or under anticoagulation therapy. 3. Infection near the site of needle insertion. 4. Body mass index \> 40kg/m2 5. Patients with any neurological or neuromuscular disorder or history of seizures. 6. Known allergy to any drug used in the study.

Design outcomes

Primary

Measure	Time frame	Description
Postoperative nausea and vomiting (PONV)	24 hours	PONV will be measured by using Verbal Descriptive Scale

Secondary

Measure	Time frame	Description
Pain	24 hours	Pain will be assessed by using visual analogue scale

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026